{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:17:41Z","timestamp":1790320661572,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.autrev.2024.103649","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T06:07:56Z","timestamp":1727676476000},"page":"103649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Tyrosine kinase 2 inhibitors in autoimmune diseases"],"prefix":"10.1016","volume":"23","author":[{"given":"Chethana","family":"Ramakrishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103649_bb0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2024.103649_bb0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0092-8674(92)90105-L","article-title":"A protein tyrosine kinase in the interferon alpha\/beta signaling pathway","volume":"70","author":"Velazquez","year":"1992","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.autrev.2024.103649_bb0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"issue":"45","key":"10.1016\/j.autrev.2024.103649_bb0020","doi-asserted-by":"crossref","first-page":"27261","DOI":"10.1074\/jbc.M115.672048","article-title":"Structural and functional characterization of the JH2 Pseudokinase domain of JAK family tyrosine kinase 2 (TYK2)","volume":"290","author":"Min","year":"2015","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.autrev.2024.103649_bb0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3934\/Allergy.2021013","article-title":"Tyk2-mediated homeostatic control by regulating the PGE2-PKA-IL-10 axis","volume":"5","author":"Muromoto","year":"2021","journal-title":"AIMS Allergy Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103649_bb0030","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/ni910","article-title":"Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock","volume":"4","author":"Karaghiosoff","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2024.103649_bb0035","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2024.103649_bb0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fimmu.2017.00029","article-title":"Canonical and non-canonical aspects of JAK\u2013STAT signaling: lessons from interferons for cytokine responses","volume":"8","author":"Majoros","year":"2017","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103649_bb0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4+ T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2024.103649_bb0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.autrev.2024.103649_bb0055","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.4049\/jimmunol.169.9.4707","article-title":"Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation","volume":"169","author":"Shimoda","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103649_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103649_bb0065","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","article-title":"L-10 family cytokines IL-10 and IL-22: from basic science to clinical translation","volume":"50","author":"Ouyang","year":"2019","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.autrev.2024.103649_bb0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.coi.2009.07.013","article-title":"Hyper-IgE syndrome","volume":"21","author":"Minegishi","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2024.103649_bb0075","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1901477","article-title":"Translating JAKs to jakinibs","volume":"204","author":"Gadina","year":"2020","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2024.103649_bb0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2024.103649_bb0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and Apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2024.103649_bb0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and Apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program fOr evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103649_bb0095","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2024.103649_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with Deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2024.103649_bb0105","series-title":"OTYKTU Prescribing Information","author":"Bristol-Myers Squibb Company","year":"2022"},{"key":"10.1016\/j.autrev.2024.103649_bb0110","author":"Bristol-Myers Squibb K.K"},{"key":"10.1016\/j.autrev.2024.103649_bb0115","year":"2023","journal-title":"Healio"},{"key":"10.1016\/j.autrev.2024.103649_bb0120","author":"National Institute for Health and Care Excellence (NICE)"},{"issue":"12","key":"10.1016\/j.autrev.2024.103649_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, Placebo-Controlled Trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"21","key":"10.1016\/j.autrev.2024.103649_bb0130","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1024\/1661-8157\/a003090","article-title":"Therapie der Psoriasisarthritis unter Ber\u00fccksichtigung neuer Behandlungsoptionen","volume":"107","author":"Ryser","year":"2018","journal-title":"Praxis"},{"key":"10.1016\/j.autrev.2024.103649_bb0135","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, Deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2024.103649_bb0140","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor Brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103649_bb0145","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-\u03b1 pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2024.103649_bb0150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.30699\/IJP.2019.94878.1934","article-title":"IL-17 is aberrantly overexpressed among under-treatment systemic lupus erythematosus patients","volume":"14","author":"Mohammadi","year":"2019","journal-title":"Iran J Pathol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103649_bb0155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind","volume":"75","author":"Morand","year":"2023","journal-title":"Placebo-Controlled Trial Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103649_bb0160","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41584-023-00932-6","article-title":"Genetics and epigenetics of primary Sj\u00f6gren syndrome: implications for future therapies","volume":"19","author":"Thorlacius","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103649_bb0165","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"7 Suppl 2","key":"10.1016\/j.autrev.2024.103649_bb0170","first-page":"6","article-title":"An Oral, selective tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC study","volume":"18","author":"Efficacy and Safety of Deucravacitinib","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"2","key":"10.1016\/j.autrev.2024.103649_bb0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","article-title":"Review: the interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2024.103649_bb0180","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Invest"},{"issue":"21","key":"10.1016\/j.autrev.2024.103649_bb0185","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1024\/1661-8157\/a003090","article-title":"Therapie der Psoriasisarthritis unter Ber\u00fccksichtigung neuer Behandlungsoptionen","volume":"107","author":"Ryser","year":"2018","journal-title":"Praxis"},{"key":"10.1016\/j.autrev.2024.103649_bb0190","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.4049\/jimmunol.0902740","article-title":"Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis","volume":"183","author":"Oyamada","year":"2009","journal-title":"J Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722400140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722400140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T16:10:08Z","timestamp":1731255008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722400140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S156899722400140X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103649","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine kinase 2 inhibitors in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103649"}}